Literature DB >> 11487023

AlphaIIbbeta3 and its antagonism at the new millennium.

E F Plow1, C S Cierniewski, Z Xiao, T A Haas, T V Byzova.   

Abstract

Because of its major role in regulating platelet functions and its prominence on the cell surface, integrin alphaIIbbeta3 has been the subject of intensive investigations. Such studies have provided substantial insights into its structure-function relationships and have led to the development of anti-thrombotic drugs that target the receptor. Nevertheless, recent findings have indicated that our understanding of the structure and function of alphaIIbbeta3 remains inadequate. This article addresses two aspects of still evolving alphaIIbbeta3 function: 1) the interface between alphaIIbbeta3 and the blood coagulation system, resulting from interaction of prothrombin with the receptor; and 2) the molecular basis for recognition of the RGD and the fibrinogen gamma-chain peptide ligands by alphaIIbbeta3. As illustrated by these two examples, there is still much to be learned about alphaIIbbeta3 if we are to fully appreciate its functions and its potential as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487023

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Comparative pharmacology of GP IIb/IIIa antagonists.

Authors:  Karsten Schrör; Artur-Aron Weber
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

Review 2.  Viral infection and human disease--insights from minimotifs.

Authors:  Krishna Kadaveru; Jay Vyas; Martin R Schiller
Journal:  Front Biosci       Date:  2008-05-01

3.  Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis.

Authors:  Anke S Lonsdorf; Björn F Krämer; Manuela Fahrleitner; Tanja Schönberger; Stephan Gnerlich; Sabine Ring; Sarah Gehring; Stefan W Schneider; Michael J Kruhlak; Sven G Meuth; Bernhard Nieswandt; Meinrad Gawaz; Alexander H Enk; Harald F Langer
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

4.  Intracellular targets of RGDS peptide in melanoma cells.

Authors:  Maria Simona Aguzzi; Paola Fortugno; Claudia Giampietri; Gianluca Ragone; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

5.  RAM, an RGDS analog, exerts potent anti-melanoma effects in vitro and in vivo.

Authors:  Maria Simona Aguzzi; Daniela D'Arcangelo; Claudia Giampietri; Maurizio C Capogrossi; Antonio Facchiano
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

6.  RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells.

Authors:  Domenica Capasso; Ivan de Paola; Annamaria Liguoro; Annarita Del Gatto; Sonia Di Gaetano; Daniela Guarnieri; Michele Saviano; Laura Zaccaro
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

7.  Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies.

Authors:  Sajad Shahbazi; Tammanna R Sahrawat; Monalisa Ray; Swagatika Dash; Dattatreya Kar; Shikha Singh
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.